Recent Updates
Recently added Catalysts
STTK Positive Sentiment

Shattuck Labs Announces Participation in Upcoming September Investor Conferences

Key Takeaway: Shattuck Labs, Inc. has announced its participation in two upcoming investor conferences, the Wells Fargo 21st Annual Healthcare Conference and the Cantor Global Healthcare Conference. CEO Taylor Schreiber and CFO Andrew Neill will present at both events, providing insights into the company's pioneering work in monoclonal and bispecific DR3 blocking antibodies. Live audio webcasts will be available for interested parties.

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in two major investor conferences
  • Presentation by CEO indicates strong leadership engagement
  • Opportunity for investors to learn about innovative therapies

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+161%
120-day peak, hindsight
Typical move
7.5%
average across 5 past catalysts
Cash runway
~64 mo
Minimal dilution risk
Lead asset
SL-325
Phase 2 · Crohn's Disease

Full Press Release Details

AUSTIN, Texas and DURHAM, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potential first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced that company management will present at and participate in the following upcoming investor conferences:

Conference Details

Wells Fargo 21 st Annual Healthcare Conference

Format: Fireside chat and one-on-one meetings Presenter: Taylor Schreiber, M.D., Ph.D., Chief Executive Officer Additional Management Participant: Andrew Neill, M.B.A., Chief Financial Officer Presentation Date: September 8, 2026 Time: 11:00 AM ET Webcast link: HERE

Cantor Global Healthcare Conference

Format: Fireside chat and one-on-one meetings Presenter: Taylor Schreiber, M.D., Ph.D., Chief Executive Officer Additional Management Participant: Andrew Neill, M.B.A., Chief Financial Officer Presentation Date: September 9, 2026 Time: 3:55 PM ET Webcast link: HERE
Interested parties can access live audio webcasts of these presentations via the Investor Relations section of the company’s website at www.shattucklabs.com. Replay webcasts will be available for approximately 30 days following the live presentations.
About Shattuck Labs, Inc. Shattuck Labs, Inc. is a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases. Shattuck’s expertise in protein engineering and the development of novel TNF receptor therapeutics come together in its lead program, SL-325, a potentially first-in-class DR3 antagonist antibody designed to achieve a more complete blockade of the clinically validated DR3/TL1A pathway. The Company has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

Investor & Media Contact: Andrew R. Neill Chief Financial Officer Shattuck Labs, Inc. InvestorRelations@shattucklabs.com

Frequently Asked Questions

When will Shattuck Labs present at the investor conferences?

Shattuck Labs will present on September 8 and 9, 2026.

Who will represent Shattuck Labs at the conferences?

CEO Taylor Schreiber and CFO Andrew Neill will represent the company.

How can I access the conference presentations?

Live audio webcasts will be available on Shattuck Labs' Investor Relations website.

What is the focus of Shattuck Labs' research?

Shattuck Labs focuses on developing DR3 blocking antibodies for inflammatory diseases.

Last updated: Sep 2, 2026